## Detailed Table of Contents

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Foreword</td>
<td>vii</td>
</tr>
<tr>
<td>Preface</td>
<td>xi</td>
</tr>
<tr>
<td>About the Contributors</td>
<td>xiii</td>
</tr>
<tr>
<td>Summary Table of Contents</td>
<td>xxv</td>
</tr>
<tr>
<td>Chapter 1. Statutory and Regulatory Controls for Drug Development</td>
<td></td>
</tr>
<tr>
<td>I. Regulation of Pharmaceuticals in the United States</td>
<td>1-2</td>
</tr>
<tr>
<td>A. Identification and Classification of Pharmaceuticals</td>
<td>1-9</td>
</tr>
<tr>
<td>B. FDA Approval Process for New Pharmaceutical Drugs</td>
<td>1-11</td>
</tr>
<tr>
<td>1. Stage 1: New Chemical Entity</td>
<td>1-12</td>
</tr>
<tr>
<td>2. Stage 2: The Investigational New Drug Application</td>
<td>1-14</td>
</tr>
<tr>
<td>a. Background on INDs</td>
<td>1-14</td>
</tr>
<tr>
<td>b. IND Application Requirements</td>
<td>1-15</td>
</tr>
<tr>
<td>c. Evaluating the Safety and Effectiveness of an Experimental Treatment Under an IND—Phase I Through III Clinical Trials [Amended Topic]</td>
<td>1-17</td>
</tr>
<tr>
<td>a. Background</td>
<td>1-18</td>
</tr>
<tr>
<td>b. FDA Process for Evaluating NDAs</td>
<td>1-20</td>
</tr>
<tr>
<td>c. FDA Standards for Denying an NDA</td>
<td>1-23</td>
</tr>
<tr>
<td>d. Unique FDA Approval Procedures for Certain Drugs</td>
<td>1-23</td>
</tr>
<tr>
<td>4. When an Abbreviated New Drug Application Is Required</td>
<td>1-26</td>
</tr>
<tr>
<td>a. Patent Law Protection and ANDAs</td>
<td>1-27</td>
</tr>
<tr>
<td>b. Hatch-Waxman Exceptions to Patent Infringement for Pharmaceuticals</td>
<td>1-28</td>
</tr>
<tr>
<td>c. FTC Regulation of ANDA-Related Activities</td>
<td>1-37</td>
</tr>
<tr>
<td>5. How the Supplemental New Drug Application Process Operates</td>
<td>1-38</td>
</tr>
<tr>
<td>C. The Approval Process for Human Biologics</td>
<td>1-39</td>
</tr>
<tr>
<td>D. FDA Postmarket Surveillance Program</td>
<td>1-43</td>
</tr>
<tr>
<td>E. Complying with FDCA Prohibitions Against Misbranding and Adulteration</td>
<td>1-48</td>
</tr>
</tbody>
</table>
1. Background ..................................................................... 1-48 —
2. FDA Enforcement Powers and Remedies ..................... 1-51 —
F. FDA Oversight of Compounded Drugs ............................. 1-53 —

II. Significant Changes to FDA Authority to Regulate Drug Development and Marketing ............................................. 1-54

A. Food & Drug Administration Amendments
Act of 2007 ........................................................................ 1-54 —
  1. Title I—Prescription Drug User Fee Amendments of 2007 and Title II—Medical Device User Fee Amendments of 2007 1-55 —
  2. Title IV—Pediatric Research Equity Act of 2007 and Title V—Best Pharmaceuticals for Children Act of 2007 1-57 —
  3. Title VI—Reagan-Udall Foundation ............................ 1-58 —
  4. Title VII—Conflicts of Interest ................................. 1-60 —
  5. Title VIII—Clinical Trial Databases ............................. 1-62 —
  6. Title IX—Enhanced Authorities Regarding Postmarket Safety of Drugs ..................................................... 1-63 —
B. The Patient Protection and Affordable Care Act ............. 1-66
  2. Labeling Changes ......................................................... 1-70 —
  3. Sunshine Act Reporting Requirements ........................ 1-70 1-11
  4. Prescription Drug Transparency ................................... 1-72 —
  5. The Cures Acceleration Network ................................. 1-72 —
D. The Future of FDA Regulatory Authority [Renumbered Topic; Substitute Text] ................................ 1-73 1-14

III. Limits of FDA Jurisdiction ........................................................ 1-74

A. The Exception for Clinical Trials of Medical Procedures Not Involving Drugs or Medical Devices ......................... 1-74 —
B. The “Practice of Medicine” Exception: Off-Label Uses of Drugs and Medical Devices ................................................. 1-74 —
C. Extraterritorial Limitations: Harmonization With Research Conducted Outside the United States ........................ 1-77 —

IV. Funding Pharmaceutical Research ............................................ 1-80

A. The Effect of Federal Funding on Research Spending ...... 1-80 —
B. Private Industry and Academic Clinical Research .......... 1-83 —
C. The Effect of FDA Approval on Reimbursement and Coverage Under Medicare & Medicaid ............................ 1-86 —

V. Marketing and Advertising Issues .............................................. 1-87

A. FTC and FDA Shared Regulation of Drug Marketing ...... 1-87 —
B. The Prescription Drug Marketing Act.............................. 1-91 —
C. Regulation of Direct-to-Consumer Advertising ................. 1-92 —
D. Potential Sanctions for Violating FDA or FTC Rules and Regulations .................................................................. 1-94 —
   1. FDA Rules—Responsible Corporate Official Liability... 1-94 —
   2. FTC Rules ..................................................................... 1-96 —

VI. Federal Agency Discretion ........................................................ 1-96

VII. Conclusion ................................................................................. 1-98 —
## Chapter 2. Key Federal Agencies Regulating Pharmaceuticals

<table>
<thead>
<tr>
<th>Volume</th>
<th>Main</th>
<th>Supplement</th>
</tr>
</thead>
<tbody>
<tr>
<td>2-1</td>
<td>2-1</td>
<td></td>
</tr>
</tbody>
</table>

### I. Introduction
- 2-2

### II. Department of Health & Human Services
- 2-3

#### A. Administrative and Enforcement Offices

1. Office of Research Integrity
2. Office of Inspector General
3. Office for Civil Rights
4. Office of Human Research Protection

#### B. HHS Divisions

1. Centers for Medicare and Medicaid Services
2. Agency for Healthcare Research and Quality
3. Centers for Disease Control and Prevention
4. Agency for Toxic Substances and Disease Registry
5. Food and Drug Administration

#### a. Office of Global Regulatory Operations and Policy

- i. Office of International Programs
- ii. Office of Regulatory Affairs

#### b. Office of Medical Products and Tobacco

- i. Center for Drug Evaluation and Research

#### (a) Office of Pharmaceutical Quality

- i (i) Office of Program and Regulatory Operations
- i (ii) Office of Policy for Pharmaceutical Quality

#### (ii) Office of Biotechnology Products

#### (iii) Office of New Drug Products

#### (iv) Office of Lifecycle Drug Products

#### (v) Office of Testing and Research

#### (vi) Office of Process and Facilities

#### (vii) Office of Surveillance

#### (viii) Office of Generic Drugs

#### (c) Office of Regulatory Policy

#### (d) Office of Executive Programs

#### (e) Office of Medical Policy

#### (f) Office of New Drugs

#### (g) Office of Communications

#### (h) Office of Compliance

- i. Office of Manufacturing and Product Quality
- ii. Office of Program and Regulatory Operations
- iii. Office of Scientific Investigations
- iv. Office of Unapproved Drugs and Labeling Compliance
(i) Office of Surveillance and Epidemiology ........................................ 2-40 —
(j) Office of Counter-Terrorism and Emergency Coordination.................. 2-40 —
(k) Office of Translational Sciences .................................................. 2-41 —
   ii. Center for Biologics and Research .............................................. 2-41 —
   iii. Center for Devices and Radiologic Health ................................ 2-45 —
   iv. Office of Special Medical Programs ........................................... 2-46 —
   v. Office of Combination Products ................................................. 2-46 —
   vi. Office of Good Clinical Practice .............................................. 2-46 —
   vii. Office of Pediatric Therapeutics ............................................. 2-47 —
   viii. Office of Orphan Products Development .................................. 2-47 —
6. Health Resources and Services Administration ................................ 2-47 2-10
7. National Institutes of Health ......................................................... 2-49 2-10
8. Substance Abuse and Mental Health Services Administration ............... 2-57 —
9. Program Support Center ................................................................. 2-57 —
III. U.S. Department of Justice ............................................................ 2-57 2-14
IV. Federal Trade Commission ............................................................. 2-61 —
V. U.S. Securities and Exchange Commission ....................................... 2-65 —
VI. U.S. Customs and Border Protection ............................................ 2-65 —
VII. U.S. Postal Service ....................................................................... 2-67 —
VIII. U.S. International Trade Commission ........................................ 2-68 —
IX. Global/International Agencies and Associations .............................. 2-68 2-14
   A. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use .................................. 2-68 —
   B. World Health Organization .......................................................... 2-69 2-14
      1. Council for International Organizations of Medical Sciences .......... 2-71 2-14
   C. United Nations Educational, Scientific and Cultural Organization ........ 2-74 —
   D. World Medical Association .......................................................... 2-74 2-16
   E. Regulatory Agencies of Other Countries ......................................... 2-76 —

Chapter 3. Federal Regulation of Advertising, Promotion, and Distribution Practices ........................................ 3-1 3-1
I. Introduction ....................................................................................... 3-3 3-3
II. FDA Regulation of Labeling and Marketing ..................................... 3-3 3-3
   A. FDA Regulation Generally ............................................................. 3-3 3-3
   B. Role of the FDA Office of Prescription Drug Promotion (Previously FDA Division of Drug Marketing, Advertising, and Communications) .............................................. 3-7 3-7
   C. FDA Regulation of Off-Label Promotion ....................................... 3-9 3-8
   D. Changes to DTC Marketing Made by the Food and Drug Administration Amendments Act of 2007 .................................................. 3-11 3-10
   E. FDA Prescription Drug Advertising Regulations .......................... 3-14 3-11
      1. FDA’s Sanction Authority [Substitute Text] .................................... 3-18 3-13
         a. FD&C Act Definitions of Misbranding and Adulterating .............. 3-18 —
<table>
<thead>
<tr>
<th>Section</th>
<th>Main Volume</th>
<th>Supplement</th>
</tr>
</thead>
<tbody>
<tr>
<td>b. Prohibited Acts: Putting an Adulterated or Misbranded Food, Drug, or Device into Interstate Commerce [Substitute Text]</td>
<td>3-19</td>
<td>3-13</td>
</tr>
<tr>
<td>c. Areas in Which Companies Have Received Warning Letters</td>
<td>3-20</td>
<td>—</td>
</tr>
<tr>
<td>2. Key Advertising Guidelines and Publications</td>
<td>3-22</td>
<td>3-14</td>
</tr>
<tr>
<td>a. Advertising and Promotion Draft Guidelines</td>
<td>3-23</td>
<td>—</td>
</tr>
<tr>
<td>b. Final Guidance on Industry-Supported Scientific and Educational Activities</td>
<td>3-24</td>
<td>—</td>
</tr>
<tr>
<td>c. FDA Guidance on Consumer-Directed Broadcast Advertisements</td>
<td>3-24</td>
<td>—</td>
</tr>
<tr>
<td>d. Direct-to-Consumer Television Advertisements—FDAAA DTC Television Ad Pre-Dissemination Review Program</td>
<td>3-25</td>
<td>—</td>
</tr>
<tr>
<td>e. FDA Research on the Effectiveness of DTC Promotion of Prescription Drugs</td>
<td>3-26</td>
<td>3-14</td>
</tr>
<tr>
<td>f. FDA Draft Recommendations on the Disclosure of Risk Information in Consumer-Directed Print Advertisements and Promotional Labeling</td>
<td>3-27</td>
<td>3-16</td>
</tr>
<tr>
<td>g. FDA Draft Guidance on “Help-Seeking” and Other Disease Awareness Communications by or on Behalf of Drug and Device Firms</td>
<td>3-31</td>
<td>3-17</td>
</tr>
<tr>
<td>h. FDA Draft Guidelines on Distributing Scientific and Medical Publications</td>
<td>3-33</td>
<td>3-19</td>
</tr>
<tr>
<td>j. FDA Draft Guidance on Medical Product Communications That Are Consistent With the FDA-Required Labeling—Questions and Answers [New Topic]</td>
<td>—</td>
<td>3-20</td>
</tr>
<tr>
<td>F. FDA Policy on Drug Importation and Modern Tensions</td>
<td>3-37</td>
<td>—</td>
</tr>
<tr>
<td>2. Exceptions to the PDMA</td>
<td>3-38</td>
<td>—</td>
</tr>
<tr>
<td>a. Imports of Pharmaceuticals and Medical Devices by Original Manufacturers</td>
<td>3-38</td>
<td>—</td>
</tr>
<tr>
<td>b. Reimportation for Emergency Use</td>
<td>3-38</td>
<td>—</td>
</tr>
<tr>
<td>3. Modern Tensions in Drug Importation</td>
<td>3-38</td>
<td>—</td>
</tr>
<tr>
<td>a. Ineffective Commercial Importation Authorization</td>
<td>3-39</td>
<td>—</td>
</tr>
<tr>
<td>b. Importation for Personal Use</td>
<td>3-42</td>
<td>—</td>
</tr>
</tbody>
</table>
III. FTC Regulation of Over-the-Counter Drug Advertising .......... 3-45 —
   A. Cooperation Between the FDA and the FTC ..................... 3-45 —
   B. Legal Framework for FTC Regulation of OTC Drug
      Advertising .............................................................. 3-45 —
      1. Enforcement Authority in the FTC Act ..................... 3-45 —
      2. FTC Policy Statements and Guides ......................... 3-46 —
         a. Deception Policy Statement ............................. 3-46 —
         b. Unfairness Policy Statement ............................ 3-47 —
         c. Statement on Advertising Substantiation ............ 3-47 —
         d. FTC Guides About the Use of Endorsements and
            Testimonials in Advertising ............................. 3-48 —
         e. FTC Statement of Policy Regarding Comparative
            Advertising ....................................................... 3-48 —
      3. FTC Remedies and Penalties .................................... 3-48 —
   C. Lessons From Particular Enforcement Actions .................. 3-49 —

IV. CMS Regulation of Prescription Drugs .................................... 3-50 —
   A. Medicare Part D: The Medicare Prescription
      Drug Benefit ............................................................ 3-51 —
      1. The Medicare Part D Transition Programs ................... 3-51 —
      2. CMS Marketing Guidelines for Prescription Drug
         Plans Under Medicare Part D and Medicare
         Advantage Programs ............................................. 3-51 —
   B. Price Reform for Part B Outpatient Drugs Under
      the MMA ..................................................................... 3-52 —
      1. Average Sales Price System .................................... 3-55 —
      2. Competitive Acquisition Program ............................ 3-57 —
   C. Fraud and Abuse Concerns for Pharmaceutical
      Manufacturers ......................................................... 3-57 —

V. Federal Preemption of State Law–Based Tort Actions ............. 3-61 —
   A. OTC Drugs .................................................................. 3-61 —
   B. Prescription Drugs .................................................... 3-62 —
   C. Medical Devices ....................................................... 3-69 —

VI. Conclusion ................................................................................. 3-72 —

Chapter 4. Potential Liability for Drug Companies, Health Care
Providers, and Insurers: Off-Label Prescribing and
Internet Advertising ..................................................................... 4-1 —

I. Introduction .............................................................................. 4-4 —

II. Impact of the Food and Drug Administration Modernization
    Act Amendments to the Food, Drug, and Cosmetic Act on
    Off-Label Use .................................................................... 4-5 —
   A. The Expansion of Permissible Promotion ..................... 4-7 —
      1. Requirements for Dissemination of Treatment
         Information on Drugs and Biologics ........................ 4-7 —
      2. Materials Eligible for Legal Dissemination ............... 4-8 —
      3. The Required Disclosures and Advance Submission
         to the FDA ............................................................. 4-9 —
      4. Submission of Supplemental Application for
         New Use or Obtaining an Exemption ........................ 4-10 —
### Detailed Table of Contents

#### B. Key Points in the FDA’s Implementing Regulations on Dissemination of Information on Unapproved/New Uses for Marketed Drugs, Biologics, and Devices

1. Key Terms Defined or Explained
   - a. Clinical Investigation
   - b. Pharmacy Benefit Manager
   - c. Supplemental Application
   - d. Unabridged Copies of a Reprint Article
   - e. “Scientifically Sound” Clinical Investigations
   - f. “False or Misleading” Information
2. Procedures for Advance Submission to the FDA
3. Criteria for Obtaining an Exemption from the Supplemental Marketing Submission Requirement on the Basis That It Would Be Unethical or Economically Prohibitive to Conduct the Required Studies
   - a. Economically Prohibitive
   - b. Unethical
4. Role of Section 401 in Increasing the Flow of Information About Off-Label Uses and in Encouraging Submission of Supplemental Marketing Applications Covering Off-Label Uses

#### III. Off-Label Prescribing Issues

A. Off-Label Prescription of Therapies
   - 1. Physician Practices in Prescribing Unapproved Therapies
      - a. Introduction
      - b. Overview of Off-Label Prescription and Promotion
      - c. Final Guidance on the Dissemination of Medical Literature About Unapproved Uses of Prescription Therapies
   - d. The FDA Revises Its Approach
      - (a) Data Source
      - (b) Distribution
      - iii. 2017 Memorandum: Public Health Interest and First Amendment Consideration Related to Manufacturer Communications Regarding Unapproved Uses of Approved or Cleared Medical Products [New Topic]
e. New FDA Initiative on Off-Label Promotion .......... 4-26 4-11

B. The Washington Legal Foundation Litigation and First Amendment Protections to Commercial Speech ................................. 4-28 4-12
1. The First Lawsuit—1993 ........................................... 4-28 —
2. Appeal to Court of Appeals and the End of WLF .......... 4-30 —
3. Thompson v. Western States Medical Center— Guidance for Off-Label Discussion ................................ — 4-31 —
4. Abigail Alliance for Better Access to Developmental Drugs v. von Eschenbach ........................................ 4-32 —
5. United States v. Caronia ............................................. 4-34 —
6. Amarin Pharma, Inc. v. United States Food & Drug Administration [Amended Topic] [Substitute Text] .... 4-35 4-12

C. Product Liability Risks for Off-Label Discussion of Prescription Products ......................................................... 4-37 4-15
1. Negligence .................................................................. 4-38 —
a. First Circuit .............................................................. 4-38 —
b. Second Circuit .......................................................... 4-38 —
c. Third Circuit ............................................................. 4-44 —
d. Fourth Circuit ........................................................... 4-44 —
e. Fifth Circuit .............................................................. 4-44 —
f. Eleventh Circuit ....................................................... 4-45 —
2. Negligence Per Se ......................................................... 4-45 —
a. Third Circuit ............................................................. 4-45 —
b. Tenth Circuit ............................................................ 4-46 —
3. Failure to Warn (Negligence or Strict Liability) ........... 4-46 —
a. Third Circuit ............................................................. 4-47 —
b. Fifth Circuit .............................................................. 4-47 —
c. Ninth Circuit ............................................................. 4-48 —
d. Eleventh Circuit ....................................................... 4-48 —
4. Fraud ............................................................................. 4-49 —
a. Tenth Circuit ............................................................ 4-49 —
b. Eleventh Circuit ....................................................... 4-50 —
5. Conspiracy .................................................................... 4-50 —
a. Third Circuit ............................................................. 4-50 —
b. Fifth Circuit .............................................................. 4-51 —
6. Unfair Competition, Consumer Fraud, and False Advertising ................................................................. 4-51 4-15
a. Seventh Circuit ........................................................ 4-51 —
7. False Claims Act .......................................................... 4-51 4-15
a. First Circuit ............................................................. 4-53 4-16
b. Second Circuit [New Topic] ......................................... 4-17
c. Third Circuit [Renumbered Topic] ............................ 4-59 4-18
d. Fourth Circuit [Renumbered Topic] ........................... 4-60 4-18
e. Fifth Circuit [Renumbered Topic] ................................. 4-61 4-18
<table>
<thead>
<tr>
<th>Main Volume</th>
<th>Supplement</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>4-18</td>
</tr>
<tr>
<td>g. Seventh Circuit [Renumbered Topic]</td>
<td>4-62</td>
</tr>
<tr>
<td>h. Eighth Circuit [Renumbered Topic]</td>
<td>4-62</td>
</tr>
<tr>
<td>i. Ninth Circuit [Renumbered Topic]</td>
<td>4-63</td>
</tr>
<tr>
<td>j. Tenth Circuit [Renumbered Topic]</td>
<td>4-64</td>
</tr>
<tr>
<td>k. Eleventh Circuit [Renumbered Topic]</td>
<td>4-64</td>
</tr>
<tr>
<td>l. D.C. Circuit [Renumbered Topic]</td>
<td>4-67</td>
</tr>
<tr>
<td>m. Arkansas [Renumbered Topic]</td>
<td>4-68</td>
</tr>
<tr>
<td>n. Texas [Renumbered Topic]</td>
<td>4-69</td>
</tr>
<tr>
<td>o. South Carolina [Renumbered Topic]</td>
<td>4-69</td>
</tr>
<tr>
<td>8. Miscellaneous</td>
<td>4-69</td>
</tr>
<tr>
<td>a. First Circuit</td>
<td>4-69</td>
</tr>
<tr>
<td>b. Seventh Circuit</td>
<td>4-70</td>
</tr>
<tr>
<td>D. Potential Defenses to Off-Label Claims</td>
<td>4-70</td>
</tr>
<tr>
<td>1. Assumption of Risk</td>
<td>4-70</td>
</tr>
<tr>
<td>2. Misuse/Unforeseeability</td>
<td>4-70</td>
</tr>
<tr>
<td>3. No Causation/Irrelevance</td>
<td>4-71</td>
</tr>
<tr>
<td>a. First Circuit [Substitute Text]</td>
<td>4-71</td>
</tr>
<tr>
<td>b. Second Circuit</td>
<td>4-71</td>
</tr>
<tr>
<td>c. Fourth Circuit</td>
<td>4-72</td>
</tr>
<tr>
<td>d. Sixth Circuit</td>
<td>4-72</td>
</tr>
<tr>
<td>e. Tenth Circuit</td>
<td>4-73</td>
</tr>
<tr>
<td>4. Learned Intermediary Doctrine</td>
<td>4-73</td>
</tr>
<tr>
<td>a. Second Circuit</td>
<td>4-76</td>
</tr>
<tr>
<td>b. Fourth Circuit</td>
<td>4-76</td>
</tr>
<tr>
<td>c. Fifth Circuit</td>
<td>4-77</td>
</tr>
<tr>
<td>d. Eleventh Circuit</td>
<td>4-77</td>
</tr>
<tr>
<td>5. Product Not Defective</td>
<td>4-78</td>
</tr>
<tr>
<td>a. Fourth Circuit</td>
<td>4-78</td>
</tr>
<tr>
<td>b. Sixth Circuit</td>
<td>4-78</td>
</tr>
<tr>
<td>6. No Reliance</td>
<td>4-79</td>
</tr>
<tr>
<td>a. Fourth Circuit</td>
<td>4-79</td>
</tr>
<tr>
<td>b. Ninth Circuit</td>
<td>4-79</td>
</tr>
<tr>
<td>IV. Internet Advertising</td>
<td>4-79</td>
</tr>
<tr>
<td>A. The Federal Food, Drug, and Cosmetic Act in the Regulation of Cyberspace</td>
<td>4-84</td>
</tr>
<tr>
<td>1. The Regulation of Product Information Content</td>
<td>4-84</td>
</tr>
<tr>
<td>2. Labeling Regulations</td>
<td>4-85</td>
</tr>
<tr>
<td>3. Advertising Regulations</td>
<td>4-86</td>
</tr>
<tr>
<td>B. Is Internet Promotion of a Product “Labeling” or “Advertising?”</td>
<td>4-89</td>
</tr>
<tr>
<td>1. FDA 1996 Notice on Unresolved Internet Issues</td>
<td>4-89</td>
</tr>
<tr>
<td>a. Presentation of Product Information</td>
<td>4-89</td>
</tr>
<tr>
<td>b. Direct-to-Consumer Promotion</td>
<td>4-90</td>
</tr>
<tr>
<td>c. Links Between Web Sites</td>
<td>4-90</td>
</tr>
<tr>
<td>d. Investigational Product Information</td>
<td>4-90</td>
</tr>
<tr>
<td>e. Chatrooms and News Groups</td>
<td>4-90</td>
</tr>
<tr>
<td>f. International Issues</td>
<td>4-90</td>
</tr>
<tr>
<td>2. Internet Advertising Ten Years Later—Little Has Changed</td>
<td>4-90</td>
</tr>
<tr>
<td>3. Social Media/Internet Platforms</td>
<td>4-92</td>
</tr>
</tbody>
</table>
Chapter 5. Federal Regulation of Clinical Research

I. Introduction [Substitute Text] ................................................... 5-2

II. Federal Common Rule and Other Relevant Rules and Regulations to Protect Human Research Subjects .......................... 5-2

A. IRBs ................................................................................... 5-3

1. Federal and State Rules ................................................ 5-3 —

2. Risk Areas ...................................................................... 5-9 —

3. Settlements, Investigations, and Litigation ................... 5-10 —

4. Continuing Review ...................................................... 5-15 —

B. A Risk-Based Approach to Clinical Trial Oversight ....... 5-17 —

C. 2017 Amendments to the Common Rule [New Topic]..... — 5-3

1. Research Exempt from the Common Rule ................... — 5-4

2. Requirements for Informed Consent ......................... — 5-5

3. Broad Consent for Research with Biospecimens or Individually Identifiable Data ..................................... — 5-6

4. Independent IRBs ........................................................ — 5-7

5. Authorization for a Single IRB for Cooperative Research — 5-8

V. Conclusion................................................................................. 4-119 —
<table>
<thead>
<tr>
<th>Detailed Table of Contents</th>
<th>Main Volume</th>
<th>Supplement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chapter 6. Avoiding Fraud and Abuse Penalties and Sanctions</td>
<td>6-1</td>
<td>6-1</td>
</tr>
<tr>
<td>I. Introduction</td>
<td>6-3</td>
<td>6-4</td>
</tr>
<tr>
<td>II. Fraud and Abuse Risk Areas for Pharmaceutical Companies</td>
<td>6-4</td>
<td>6-5</td>
</tr>
</tbody>
</table>

6. Criteria for IRB Approval of Research
7. Ongoing IRB Review of Research
8. Posting of Informed Consent Forms
9. Proposed Changes Not Adopted in the Final Rule

III. Informed Consent
A. Federal and State Rules
B. Risk Areas
   1. Therapeutic Misconceptions
   2. The Form
C. Settlements, Investigations, and Litigation

IV. Conflicts of Interest
A. FDA-Regulated Research
B. PHS-Funded Research
C. Risk Areas
D. Settlements, Investigations, and Litigation

V. Research Misconduct
A. HHS Office of Research Integrity
   1. Initial Institutional Inquiry
   2. Institutional Investigation
B. Food and Drug Administration
   1. Human Subject Protection/Bioresearch Monitoring Initiative
   2. FDA-Regulated Clinical Research Performed Outside the United States
C. Risk Areas
D. Settlements, Investigations, and Litigation

VI. Reporting Requirements
A. Reporting Adverse Events
B. Reporting Related to Clinical Trial Registries

VII. Time and Expense Reporting for Federal Research Grants
A. Reporting by Grantee Institutions and Investigators
B. Risk Areas and Settlements

VIII. Reimbursement of Drugs Used During Clinical Trials Under Medicare Parts A and B
A. Medicare Coverage for Routine Costs Associated With Clinical Trials
B. Criteria for Coverage
   1. Routine Costs
   2. Qualified Trials
      a. Deemed Qualified
      b. Qualifying
      c. Policy Considerations and Risk Areas
IX. Conclusion
III. Fraud and Abuse Enforcement Authorities ...................... 6-8 6-6
   A. Medicare and Medicaid Anti-Kickback Statute .......... 6-8 6-6
      1. Overview of Anti-Kickback Statute ................. 6-8 —
      2. Elements of Anti-Kickback Offense .................. 6-10 —
         a. Knowingly and Willfully ......................... 6-10 —
         b. Solicitation or Receipt of Remuneration ....... 6-11 —
         c. In Exchange for or to Induce a Business Referral or
            in Exchange for Purchasing, Leasing, Ordering, or
            Arranging for Program-Related Goods, Facilities,
            Services, or Items ........................................ 6-11 —
      3. Exceptions in the Statute and Safe Harbor
         Regulations .................................................. 6-11 6-6
         a. Discount Safe Harbor ............................... 6-13 —
         b. Group Purchasing Organizations ................. 6-14 —
            i. GPO Agreement ................................... 6-14 —
            ii. Disclosure Requirement ...................... 6-14 —
         c. Personal Services Contracts .................... 6-14 —
         d. Warranties ............................................. 6-15 —
         e. Employees .............................................. 6-16 —
            i. Medicare Coverage Gap Discounts [New Topic]... — 6-8
            ii. Free or Discounted Local Transportation
                [New Topic] ............................................ — 6-8
                  i. FQHCs and Medicare Advantage Organizations
                     [New Topic] ........................................... 6-9
                  ii. Safe Harbor for Cost-Sharing Waivers
                     [New Topic] ........................................... — 6-10
      4. Anti-Kickback Compliance Guidance from the
         HHS OIG ...................................................... 6-16 6-10
         a. OIG Guidance ........................................... 6-17 6-10
            i. OIG Compliance Program Guidance for
               Pharmaceutical Manufacturers .................... 6-17 6-10
               (a) Overview of the OIG Compliance
                   Guidance .............................................. 6-17 —
               (b) Specific Risk Areas ............................ 6-19 —
                  (1) Integrity of Data Used by State and
                       Federal Governments to Establish
                       Payment Amounts ............................... 6-19 —
                  (2) Kickbacks and Other Illegal
                       Remuneration ...................................... 6-20 —
                       (A) Relationships With Purchasers
                           and Their Agents .............................. 6-21 —
                       (B) Relationships With Physicians
                           and Other Persons and Entities
                           in a Position to Make or
                           Influence Referrals ........................... 6-22 —
                       (C) Relationships With Sales Agents ... 6-23 —
<table>
<thead>
<tr>
<th>Main Volume</th>
<th>Supplement</th>
</tr>
</thead>
<tbody>
<tr>
<td>(c) Providing Drug Samples</td>
<td>6-23</td>
</tr>
<tr>
<td>ii. Prescription Drug Marketing Schemes</td>
<td>6-24</td>
</tr>
<tr>
<td>iii. Copayment Coupons</td>
<td>6-25</td>
</tr>
<tr>
<td>iv. Up-Front Rebates, Prebates, and Signing Bonuses</td>
<td>6-26</td>
</tr>
<tr>
<td>b. OIG Advisory Opinions</td>
<td>6-27</td>
</tr>
<tr>
<td>i. OIG Advisory Opinion No. 00–5</td>
<td>6-27</td>
</tr>
<tr>
<td>ii. OIG Advisory Opinion No. 00–10</td>
<td>6-28</td>
</tr>
<tr>
<td>iii. OIG Advisory Opinion No. 02–13</td>
<td>6-30</td>
</tr>
<tr>
<td>iv. OIG Advisory Opinion No. 02–16</td>
<td>6-31</td>
</tr>
<tr>
<td>v. OIG Advisory Opinion No. 03–3</td>
<td>6-32</td>
</tr>
<tr>
<td>vi. Medicare Part D Advisory Opinions</td>
<td>6-33</td>
</tr>
<tr>
<td>vii. OIG Advisory Opinion No. 07-17</td>
<td>6-34</td>
</tr>
<tr>
<td>viii. OIG Advisory Opinion No. 08-04</td>
<td>6-34</td>
</tr>
<tr>
<td>ix. OIG Advisory Opinion No. 08-05</td>
<td>6-35</td>
</tr>
<tr>
<td>x. OIG Advisory Opinion No. 08-11 and Modification to Advisory Opinion No. 08-11</td>
<td>6-36</td>
</tr>
<tr>
<td>xi. OIG Advisory Opinion No. 11-07</td>
<td>6-37</td>
</tr>
<tr>
<td>xii. OIG Advisory Opinion No. 10-19</td>
<td>6-37</td>
</tr>
<tr>
<td>xiii. Revised OIG Advisory Opinion No. 07-18</td>
<td>6-38</td>
</tr>
<tr>
<td>xiv. Revised OIG Advisory Opinion No. 07-06</td>
<td>6-39</td>
</tr>
<tr>
<td>xv. OIG Advisory Opinion No. 12-10</td>
<td>6-40</td>
</tr>
<tr>
<td>xvi. OIG Advisory Opinion No. 12-19</td>
<td>6-41</td>
</tr>
<tr>
<td>xvii. OIG Advisory Opinion No. 13-07</td>
<td>6-44</td>
</tr>
<tr>
<td>xviii. OIG Advisory Opinion No. 14-05</td>
<td>6-44</td>
</tr>
<tr>
<td>xix. OIG Advisory Opinion No. 14-06</td>
<td>6-46</td>
</tr>
<tr>
<td>xx. OIG Advisory Opinion No. 15-06</td>
<td>6-47</td>
</tr>
<tr>
<td>5. Investigations, Settlements, and Litigation</td>
<td>6-48</td>
</tr>
<tr>
<td>B. Federal Civil False Claims Act</td>
<td>6-62</td>
</tr>
<tr>
<td>1. Historical Overview</td>
<td>6-62</td>
</tr>
<tr>
<td>a. Original Text</td>
<td>6-62</td>
</tr>
<tr>
<td>b. 1943 Amendments</td>
<td>6-63</td>
</tr>
<tr>
<td>e. 1986 Amendments</td>
<td>6-63</td>
</tr>
<tr>
<td>d. 1986 to Present</td>
<td>6-64</td>
</tr>
<tr>
<td>e. 2009 Amendments</td>
<td>6-64</td>
</tr>
<tr>
<td>f. 2010 Amendment</td>
<td>6-67</td>
</tr>
<tr>
<td>2. Elements of a False Claim</td>
<td>6-69</td>
</tr>
<tr>
<td>a. 31 U.S.C. §3729(a)(1)</td>
<td>6-70</td>
</tr>
<tr>
<td>i. Presentation of a Claim to the Government</td>
<td>6-70</td>
</tr>
<tr>
<td>ii. Falsity of the Claim</td>
<td>6-70</td>
</tr>
<tr>
<td>(a) Factual Falsity</td>
<td>6-71</td>
</tr>
<tr>
<td>(b) Worthless Services</td>
<td>6-71</td>
</tr>
<tr>
<td>(c) Legal Falsity</td>
<td>6-71</td>
</tr>
<tr>
<td>(d) Express Legal Falsity</td>
<td>6-71</td>
</tr>
<tr>
<td>(e) Implied Legal Falsity [Substitute Text]</td>
<td>6-72</td>
</tr>
<tr>
<td>iii. Knowledge of the Falsity of the Claim</td>
<td>6-72</td>
</tr>
</tbody>
</table>
### 3. False Claims Act and Other Civil Monetary Penalties

Dramatically Increased [Amended Topic] .............................................. 6-75

4. FCA Enforcement ......................................................... 6-75
   a. Settlements ............................................................... 6-75
   b. Qui Tam Claims ....................................................... 6-85
      i. 31 U.S.C. §3730(c)(4)(A) ................................. 6-85
      ii. Liability of Municipal Corporations ................. 6-86
   c. Research Grants ....................................................... 6-89

5. Application of the FCA and Risk Areas ........................................ 6-87
   a. Other Statutory Predicates for False Claims Act Cases ................................................ 6-87
   b. Sales and Marketing ................................................. 6-87
   c. Research Grants ....................................................... 6-89

C. Health Care Fraud Statute .................................................. 6-93
   1. Overview of the Statute .............................................. 6-93
   2. Penalties ............................................................... 6-94
   3. Settlements and Investigations ..................................... 6-95

D. Civil Monetary Penalties Law ........................................... 6-97
   1. Legislative History ........................................................ 6-98
   2. Overview of the Civil Monetary Penalties Law ........... 6-99
   3. Civil Monetary Penalties Provisions of Particular Relevance ........................................ 6-100
      a. False Claims ............................................................. 6-100
      b. Beneficiary Inducements ........................................ 6-101
      c. Excluded Individuals ............................................... 6-102
      d. CMPs for Anti-Kickback Claims ................................... 6-102
      e. CMPs and the Medicare Prescription Drug, Improvement, and Modernization Act ............. 6-103
      f. CMPs and the Patient Protection and Affordable Care Act ........................................ 6-104
      g. 2016 Amendments to the Definition of Remuneration Under the Civil Monetary Penalties Law [New Topic] ................................................ 6-26

4. OIG and Civil Monetary Penalties in Practice ............. 6-105

E. Ethics in Patient Referrals Act of 1989 .............................. 6-105
   1. Historical Overview ...................................................... 6-105
   2. Overview of the Current Statute ................................... 6-106
   3. Stark Exceptions Applicable to Pharmaceutical Research ........................................ 6-107
      a. Physician Services and In-Office Ancillary Services ........................................ 6-107
      b. Academic Medical Centers ...................................... 6-109

F. Exclusions from Participating in Federally Funded Health Care Programs ........................................ 6-110
   1. Mandatory Exclusions ........................................ 6-110
   2. Permissive Exclusions ........................................ 6-111
   3. Effect of an Exclusion ........................................ 6-113

IV. Conclusion ................................................................................. 6-114
Chapter 7. Regulation of Privacy Under HIPAA and Other Privacy Laws

I. Introduction

II. The Common Rule and Regulations for the Protection of Human Subjects

III. HIPAA
   A. Background
   B. Covered Entity
   C. Protected Health Information
   D. De-Identification
   E. Information Created or Received by a Covered Entity

IV. Disclosure of PHI
   A. Permissible Disclosures
   B. Authorized Disclosures
   C. Certificates of Confidentiality

V. HIPAA Applicability to Pharmaceutical Manufacturers and Distributors
   A. Direct Coverage Under HIPAA
   B. Indirect Coverage under HIPAA
   C. Marketing and Promotion Issues

VI. HIPAA’s Additional Requirements for Conducting Research
   A. Obtaining a Patient’s Written Authorization Before Using or Disclosing PHI for Research
   B. Authorization
   C. Requirements for a Valid Authorization
      1. Core Elements
         a. Identity of the Party Authorizing the PHI Disclosure
         b. Identity of the Party Receiving the PHI Disclosure
         c. Identity of the Person Who Provides the Disclosure of PHI
         d. Description of Information for Disclosure of PHI
         e. Purpose for Disclosure of the PHI
         f. An Expiration Date or Event
         g. Date of Signature
      2. Required Statements
         a. Individual’s Right to Revoke
         b. Treatment Not Conditioned on Signing the Authorization
         c. Redisclosure of PHI
      3. Other Considerations
         a. Plain Language
         b. Individual Receives a Copy of the Authorization
         c. Copy Is as Valid as Original Authorization
         d. Authorizations Prepared by Third Parties
         e. No Specific Format
         f. Cover Letter Accompanying the Authorization
Pharmaceutical Law—2018 Supplement

D. Exceptions to a Written Authorization ............................... 7-25 —
   1. Documented Institutional Review Board or Privacy Board Approval. ............. 7-26 —
   2. Limited Data Sets With a Data Use Agreement. ....... 7-29 —
   3. Preparation for Research............................................ 7-30 —
   4. Research on PHI of Decedent ....................................... 7-31 —

E. Making Reasonable Efforts to Limit the Use or Disclosure of PHI to the Minimum Necessary to Accomplish the Intended Purpose .................................................. 7-31 —

VII. Compliance With HIPAA Security Rule ................................... 7-32 —
   A. Administrative Safeguards ................................................. 7-33 —
      1. Security Management Process ...................................... 7-34 —
         a. Risk Assessments ..................................................... 7-34 —
         b. Sanction Policy and Information System Activity Review ........................................ 7-35 —
      2. Assigned Security Responsibility ................................. 7-35 —
      3. Workforce Security ....................................................... 7-36 —
      4. Information Access Management .................................. 7-36 —
      5. Security Awareness and Training .................................. 7-37 —
      6. Security Incident Procedures ........................................ 7-38 —
      7. Contingency Plan .......................................................... 7-38 —
      8. Evaluation ..................................................................... 7-39 —
      9. Business Associate Requirements ................................. 7-39 —
   B. Physical Safeguards ........................................................... 7-41 —
      1. Facility Access Control ................................................. 7-41 —
      2. Workstation Use ............................................................ 7-42 —
      3. Workstation Security ..................................................... 7-43 —
      4. Device and Media Controls .......................................... 7-43 —
   C. Technical Safeguards ......................................................... 7-44 —
      1. Access Control .............................................................. 7-44 —
      2. Audit Control .............................................................. 7-45 —
      3. Integrity ......................................................................... 7-46 —
      4. Person or Entity Authentication .................................... 7-46 —
      5. Transmission Security ................................................... 7-47 —
   D. Documentation Requirements ............................................ 7-47 —

VIII. Recent Developments................................................................ 7-48 —
   A. HITECH Act ...................................................................... 7-48 —
      1. Breach Notification........................................................ 7-48 —
      2. Guidance for Technologies and Methodologies That Render PHI Unusable, Unreadable, or Indecipherable to Unauthorized Individuals........................................ 7-50 —
      3. Restrictions for the Remuneration of PHI .................... 7-51 —
   B. Genetic Information Nondiscrimination Act of 2008 ........... 7-51 —
      1. GINA Overview ........................................................... 7-51 —
      2. Penalties ........................................................................ 7-52 —
      3. Specific Research Provisions ........................................ 7-52 —
   C. HIPAA Enforcement ......................................................... 7-53 —
      1. Statistics and OIG Reports [Amended Topic; Substitute Text] ........................................ 7-53 —

Main
Volume
7-24
7-25
7-26
7-29
7-30
7-31
7-32
7-33
7-34
7-35
7-36
7-37
7-38
7-39
7-39
7-40
7-41
7-41
7-42
7-43
7-43
7-44
7-44
7-45
7-46
7-46
7-47
7-47
7-48
7-48
7-48
7-48
7-50
7-51
7-51
7-52
7-52
7-53
7-53
7-53
1.1. HIPAA Enforcement Activity Statistics

[New Topic] ................................................................. — 7-8

2. HITECH Act ............................................................... 7-53 —

3. Outpatient Surgical Facility Corrects Privacy Procedure in Research Recruitment 7-54 —

4. CVS Caremark Corporation ........................................ 7-54 —

5. Civil Penalties Modified .......................................... 7-55 —


8. Massachusetts General Hospital ................................ 7-58 —

9. Cignet Health .............................................................. 7-59 —

10. University of California at Los Angeles Health System .......................................................... 7-60 —

11. Blue Cross Blue Shield of Tennessee ......................... 7-60 —

12. Phoenix Cardiac Surgery, PC .................................. 7-61 —

13. Alaska Department of Health and Social Services .... 7-61 —

14. Massachusetts Eye and Ear Infirmary and Massachusetts Eye and Ear Associates, Inc. ............... 7-62 —

15. WellPoint, Inc. ............................................................. 7-63 —

16. Affinity Health Plan, Inc. ........................................ 7-63 —

17. Adult & Pediatric Dermatology, P.C. ......................... 7-64 —

18. Skagit County, Washington ..................................... 7-64 —

19. Concentra Health Services ........................................ 7-65 —

20. New York and Presbyterian Hospital and Columbia University ........................................................................ 7-65 7-21

21. Parkview Health System, Inc .................................... 7-66 —

22. Cornell Prescription Pharmacy ................................... 7-66 —

23. Felony Violation of HIPAA by Anchorage Woman .... 7-67 —

24. St. Elizabeth’s Medical Center .................................. — 7-21

25. Cancer Care Group, P.C. .......................................... — 7-22

26. Lahey Hospital and Medical Center ........................... — 7-22

27. Triple-S Management Corporation ............................ — 7-23

28. University of Washington Medicine .......................... — 7-23

29. Lincare, Inc. ................................................................ — 7-24

30. Complete P.T., Pool & Land Physical Therapy, Inc. ... — 7-25

31. Importance of Business Associate Agreements........... — 7-25

32. Feinstein Institute and Research Participants’ PHI ..... — 7-26

33. New York Presbyterian Hospital ............................... — 7-27

34. Catholic Health Care Services of the Archdiocese of Philadelphia .......................................................... — 7-27

35. Oregon Health & Science University .......................... — 7-28

36. University of Mississippi Medical Center .................. — 7-28

37. Advocate Health Care Network ................................. — 7-28

38. Care New England Health System ............................. — 7-29

39. St. Joseph Health ......................................................... — 7-30

40. University of Massachusetts Amherst ........................ — 7-30

41. Presence Health ........................................................... — 7-31

42. MAPFRE Life Insurance Company of Puerto Rico... — 7-31
43. Children’s Medical Center of Dallas
44. Memorial Healthcare Systems
45. Metro Community Provider Network
46. The Center for Children’s Digestive Health
47. CardioNet, Inc.
50. 21st Century Oncology, Inc. [New Topic]
51. HIV Privacy Class Action Lawsuit Against Aetna Insurance Company [New Topic]
52. Fresenius Medical Care North America [New Topic]
53. Receiver Acting on Behalf of Filefax, Inc. [New Topic]
54. Virtua Medical Group, P.A. [New Topic]

D. Accounting of Disclosures Under HIPAA and HITECH
E. Office for Civil Rights HIPAA Audit Program

IX. Conclusion


I. Introduction [Substitute Text]
II. Structure and Navigation of Corporate Compliance
   A. Federal Sentencing Guidelines for Organizations:
      1. Structure of Corporate Compliance
      2. Restitution and Remediation
      3. The Fine
      4. Probation
      5. Special Assessments, Forfeitures, and Costs
      6. Effective Compliance and Ethics Program Under the Organizational Guidelines
      7. Seven General Requirements for an Effective Compliance Plan
      8. Factors to Consider in Evaluating the Effectiveness of an Organization’s Compliance Plan
      9. Focus on the Compliance Role of Individuals With Organizational Authority
      10. Expectations of Monitoring, Auditing, and Detecting Criminal Activity
   B. Securities Laws: Internal Control Requirements for Issuers (FCPA and SOX)
   C. Federal Acquisition Regulations: Mandatory Disclosure and Amplified Compliance Programs for Government Contractors
      1. Requirement of a Compliance Program for Certain Federal Contractors
      2. Mandatory Disclosure of Violations
### Detailed Table of Contents

<table>
<thead>
<tr>
<th>Main Volume</th>
<th>Supplement</th>
</tr>
</thead>
<tbody>
<tr>
<td>3. Failure to Disclose as a Cause for Suspension and Debarment</td>
<td>8-23</td>
</tr>
<tr>
<td>4. Contractor Internal Control System Requirements</td>
<td>8-23</td>
</tr>
<tr>
<td><strong>D. Voluntary Disclosures to Government Agencies:</strong></td>
<td></td>
</tr>
<tr>
<td>1. Potential Benefits of Voluntary Disclosures</td>
<td>8-24</td>
</tr>
<tr>
<td>2. Likelihood of Whistleblower</td>
<td>8-25</td>
</tr>
<tr>
<td>3. Potential Risks in Making a Voluntary Disclosure</td>
<td>8-26</td>
</tr>
<tr>
<td>b. Potential Drawbacks of the OIG’s 2013 SDP [Renumbered Topic]</td>
<td>8-28</td>
</tr>
<tr>
<td>c. Selective Waiver of Privilege and Collateral Litigation [Renumbered Topic]</td>
<td>8-28</td>
</tr>
<tr>
<td>d. Compelled Waiver of Privilege [Renumbered Topic; Substitute Text]</td>
<td>8-29</td>
</tr>
<tr>
<td>ii. Indemnification of Legal Fees—The Stein Court Decision</td>
<td>8-30</td>
</tr>
<tr>
<td>iii. SEC Enforcement Manual</td>
<td>8-31</td>
</tr>
<tr>
<td>iv. SEC Program: Assessing Cooperation by Individuals</td>
<td>8-32</td>
</tr>
<tr>
<td>e. Incomplete Disclosures and New Investigations [Renumbered Topic]</td>
<td>8-34</td>
</tr>
<tr>
<td>f. The Decision [Renumbered Topic]</td>
<td>8-35</td>
</tr>
<tr>
<td><strong>III. Role and Risk for Corporate Stakeholders:</strong></td>
<td></td>
</tr>
<tr>
<td>A. Caremark and Its Progeny: Relevance of the Board to Effective Compliance Measures</td>
<td>8-35</td>
</tr>
<tr>
<td>1. The Caremark Case</td>
<td>8-36</td>
</tr>
<tr>
<td>2. Evolution of the Caremark Claim</td>
<td>8-38</td>
</tr>
<tr>
<td>3. Effects of Caremark on Subsequent Findings of Board of Directors Liability</td>
<td>8-40</td>
</tr>
<tr>
<td>B. Government Targeting Corporate Executives for Prosecution and Exclusion</td>
<td>8-42</td>
</tr>
<tr>
<td>1. Responsible Corporate Officer Doctrine</td>
<td>8-43</td>
</tr>
<tr>
<td>2. OIG Guidance for Implementing Permissive Exclusion Authority Under Social Security Act Section 1128(b)(15)</td>
<td>8-45</td>
</tr>
<tr>
<td>3. FDA Procedures and Criteria for Prosecution of Corporate Officers</td>
<td>8-46</td>
</tr>
<tr>
<td>4. Amendments to U.S. Sentencing Guidelines for Park Doctrine Prosecutions</td>
<td>8-47</td>
</tr>
<tr>
<td><strong>IV. Government and Industry Compliance Guidance:</strong></td>
<td></td>
</tr>
<tr>
<td>A. 2003 OIG Compliance Program Guidance for Pharmaceutical Manufacturers</td>
<td>8-48</td>
</tr>
<tr>
<td>1. Basic Compliance Elements</td>
<td>8-48</td>
</tr>
<tr>
<td>2. Identified Risk Areas</td>
<td>8-49</td>
</tr>
<tr>
<td>a. Data Integrity Used to Establish Payment</td>
<td>8-49</td>
</tr>
<tr>
<td>b. Kickbacks and Other Improper Remuneration</td>
<td>8-50</td>
</tr>
<tr>
<td>c. Relationships With Purchasers and Their Agents</td>
<td>8-51</td>
</tr>
</tbody>
</table>
### d. Relationships With Physicians and Other Persons and Entities in a Position to Make or Influence Referrals
- 8-54

### e. Relationships With Sales Agents
- 8-56

### f. Compliance With FDA Rules Regarding Drug Samples
- 8-57

#### B. Role of Industry Compliance Guidance
- 8-57

1. PhRMA Code on Interactions With Health Care Professionals
   - a. Meals
   - 8-59
   - b. Continuing Medical Education
   - 8-59
   - c. Consultants and Speakers
   - 8-59
   - d. Formulary Committee Members
   - 8-60
   - e. Gifts
   - 8-60
   - f. Data
   - 8-60
   - g. Training
   - 8-60
   - h. Annual Certification
   - 8-61

2. Advanced Medical Technology Association Code of Ethics on Interactions With Health Care Professionals
   - a. Code of Ethics Compliance
   - 8-61
   - b. Types of Arrangements Discussed
   - 8-61
     - i. Consulting Arrangements and Royalties
     - 8-61
     - ii. Prohibition on Entertainment and Recreation
     - 8-62
     - iii. Modest Meals Associated With HCP Business Interactions
     - 8-62
     - iv. Educational Items: Prohibition on Gifts
     - 8-63
     - v. Provision of Coverage, Reimbursement, and Health Economics Information
     - 8-63
     - vi. Evaluation and Demonstration Projects
     - 8-64
     - vii. Direct Sponsorship of HCP Education
     - [New Topic]

3. HGPII Code of Conduct Principles
   - a. HSCA and HGPII Background
   - 8-64
   - b. HGPII Code of Conduct Principles
   - 8-64
   - c. Written Code of Business Conduct
   - 8-65
   - d. Employee Training
   - 8-65
   - e. Quality and Cost-Effectiveness
   - 8-65
   - f. Conflict of Interest Policies
   - 8-66
   - g. Best Practices
   - 8-66
   - h. Accountability to the Public
   - 8-67

4. Guidance From the DOJ and SEC
- 8-67

#### C. Practice Guideposts for Applying Compliance Guidance
- 8-68

---

**Chapter 9. The FDA Approval Process for New Drugs**

   - 9-3

   A. The Federal Food and Drugs Act of 1906
   - 9-3
### Detailed Table of Contents

**Main Volume**

<table>
<thead>
<tr>
<th>Section</th>
<th>Pages</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>B. The Food, Drug, and Cosmetic Act of 1938</strong></td>
<td>9-7</td>
</tr>
<tr>
<td>1. The Factory Inspection Provision</td>
<td>9-8</td>
</tr>
<tr>
<td>2. Drug Safety Requirements</td>
<td>9-9</td>
</tr>
<tr>
<td>3. The New Drug Applications</td>
<td>9-10</td>
</tr>
<tr>
<td><strong>C. The Durham-Humphrey Amendment</strong></td>
<td>9-11</td>
</tr>
<tr>
<td><strong>D. The Kefauver-Harris Amendments</strong></td>
<td>9-12</td>
</tr>
<tr>
<td>2. Drug Labeling</td>
<td>9-14</td>
</tr>
<tr>
<td>3. Factory Inspections</td>
<td>9-15</td>
</tr>
<tr>
<td><strong>E. The Hatch-Waxman Amendments</strong></td>
<td>9-15</td>
</tr>
<tr>
<td><strong>II. The Approval Process for New Drugs</strong></td>
<td>9-19</td>
</tr>
<tr>
<td>A. The Road to Approval</td>
<td>9-19</td>
</tr>
<tr>
<td>1. Understanding the Different Phases of Drug Development</td>
<td>9-19</td>
</tr>
<tr>
<td>2. Introduction to Research Protocols</td>
<td>9-21</td>
</tr>
<tr>
<td>3. Preclinical Drug Development</td>
<td>9-21</td>
</tr>
<tr>
<td>4. The Investigational New Drug Application</td>
<td>9-22</td>
</tr>
<tr>
<td>5. Submitting the IND</td>
<td>9-25</td>
</tr>
<tr>
<td>6. The Post-IND Submission Period</td>
<td>9-26</td>
</tr>
<tr>
<td>7. The IND Review Process</td>
<td>9-27</td>
</tr>
<tr>
<td><strong>B. Clinical Holds</strong></td>
<td>9-28</td>
</tr>
<tr>
<td><strong>C. Clinical Trials</strong></td>
<td>9-29</td>
</tr>
<tr>
<td><strong>D. Bypassing Clinical Phase Trials</strong></td>
<td>9-30</td>
</tr>
<tr>
<td><strong>E. The Post-Clinical Trial, Pre-NDA Window</strong></td>
<td>9-31</td>
</tr>
<tr>
<td><strong>III. The NDA/ANDA Process: To Be or Not to Be Approved</strong></td>
<td>9-31</td>
</tr>
<tr>
<td>A. The NDA Process</td>
<td>9-31</td>
</tr>
<tr>
<td>1. Historical Development of the NDA Process</td>
<td>9-32</td>
</tr>
<tr>
<td>2. The Current NDA</td>
<td>9-32</td>
</tr>
<tr>
<td>3. NDA Classifications</td>
<td>9-34</td>
</tr>
<tr>
<td>B. NDA Review of Completed Applications</td>
<td>9-34</td>
</tr>
<tr>
<td><strong>IV. Generic Drugs: The ANDA Process</strong></td>
<td>9-37</td>
</tr>
<tr>
<td>A. Understanding How and When Pharmaceuticals Become Eligible Under the 1984 Hatch-Waxman Amendments</td>
<td>9-37</td>
</tr>
<tr>
<td>1. Reverse Payment Settlement Agreements: How Federal Courts Determine Whether an Antitrust Violation has Occurred</td>
<td>9-46</td>
</tr>
<tr>
<td>B. How the ANDA Application, Notice, and Content Requirements Work</td>
<td>9-50</td>
</tr>
<tr>
<td>1. FDA Standards for Approving ANDAs</td>
<td>9-50</td>
</tr>
<tr>
<td>iii. FDA Proposed Rule: Supplemental Applications Proposing Labeling Changes for Approved Drugs and Biological Products [New Topic]</td>
<td>9-9</td>
</tr>
</tbody>
</table>
2. Over-the-Counter (OTC) Medications [Amended Topic] ............................................................................. 9-17
   a. The OTC Approval Process ..................................... 9-17
   b. The OTC Review Process ........................................ 9-18
   c. Marketing OTC Drugs [Renumbered Topic] ............ 9-20

C. How the Food, Drug, and Cosmetic Act New Drug Application Operates ......................................................... 9-56
   1. Basic Section 505(b)(2) Requirements ......................... 9-60
   2. The Section 505(b)(2) Application ............................... 9-61
   3. Core Standards for Obtaining Approval of Section 505(b)(2) Applications .................................................. 9-61

V. Biologic and Biosimilar Products, The Biologic Price Competition and Innovation Act, and the Biosimilar Market... 9-62
   A. Biologic Products [Substitute Text] ................................... 9-62
         c. FDA-Approved Biosimilars [Amended/Renumbered Topic; Substitute Text] 9-64
         g. The Biosimilar Product Market [Renumbered Topic] ........................................... 9-67
         h. Postmarketing Safety Monitoring Considerations [Renumbered Topic] .................... 9-68

VI. How the Federal Common Rule, FDA’s Human Research Subject Protections, and Other Regulatory Mechanisms Provide Regulatory Protection to the FDA Drug Application Process ................................................................. 9-69
   A. The Federal Common Rule ................................................ 9-71
      1. Institutional Review Boards ......................................... 9-72
      2. Federalwide Assurances ................................................ 9-75
         a. Minimum Federalwide Assurance Principles ............ 9-75
         b. Specifics of Federalwide Assurances ....................... 9-77
### Detailed Table of Contents

| i. Human Subjects Research Must be Guided by a Statement of Principles | 9-77 | — |
| ii. Applicability | 9-77 | — |
| iii. Compliance With Laws, Regulations, Policies, and Guidelines | 9-77 | — |
| iv. Written Procedures | 9-77 | — |
| v. Institutional Support for the IRB(s) | 9-78 | — |
| vi. Reliance on an External IRB | 9-78 | — |
| vii. Renewal or Update of the Assurance | 9-78 | — |
| 3. Informed Consent | 9-78 | — |
| B. Advisory Committees | 9-79 | — |
| C. Current Good Manufacturing Practices | 9-80 | — |
| 2. Control of Components, Drug Product Containers, and Closures | 9-86 | — |
| 3. Production and Process Controls | 9-87 | — |
| 4. Packaging and Labeling Control | 9-87 | — |
| 5. Drug Holding and Distribution | 9-89 | — |
| 6. Laboratory Controls | 9-89 | — |
| 7. Records and Reports | 9-91 | — |
| 8. Returned and Salvaged Drug Products | 9-92 | — |

### Chapter 10. State Regulatory Schemes for Pharmaceuticals and Related Issues

| I. Introduction [Substitute Text] | 10-2 | 10-2 |
| II. Direct-to-Consumer Advertising and the Marketing of Pharmaceuticals | 10-2 | 10-2 |
| B. Pharmacy Benefit Manager Laws [Renumbered Topic] | 10-3 | 10-4 |
| a. PBM Fiduciary Status Relationship Defined | 10-4 | — |
| b. UPDPA PBM Mandatory Disclosures | 10-5 | — |
| c. Therapeutic Substitutions | 10-6 | — |
| d. Pharmaceutical Care Management Association v. Rowe | 10-6 | — |
| 2. The District of Columbia Access Rx Act | 10-8 | — |
| 3. The South Dakota PBM Act | 10-9 | — |
| 4. The North Dakota PBM Act | 10-9 | — |
   1. The West Virginia Pharmaceutical Availability and Affordability Act ........................................ 10-12 —
   3. California Resolution 24 ......................................................... 10-13 —

   1. The Vermont Pharmacy Best Practices and Cost Control Program Act ........................................... 10-14 —
   3. The Minnesota Gifts to Practitioners Act ................................................... 10-16 —

E. Pharmaceutical Research and Manufacturers of America [Renumbered Topic] .......................................................... 10-16 10-10

Chapter 11. Antitrust and Intellectual Law Issues for Pharmaceutical Companies............................................ 11-1 11-1

I. Introduction ............................................................................... 11-3 —

II. Major Federal Antitrust Laws ................................................... 11-8 11-3
   A. The Sherman Act ................................................................ 11-17 —
   B. The Clayton Act ................................................................ 11-31 —
   C. The FTC Act ...................................................................... 11-34 —
   D. Antitrust Standards ............................................................. 11-37 —
       1. The Per Se Rule ............................................................ 11-37 —
       2. The Rule of Reason ...................................................... 11-40 —
           a. The Relevant Market..................................................... 11-41 —
               i. Defining the Market ........................................ 11-42 —
               ii. Measuring the Market: The Herfindahl-Hirschman Index ........................................ 11-44 —
           b. The Harm Caused by Restraints to Competition .... 11-44 —
           c. The Overall Effects on Competition ...................... 11-45 —
       3. The Quick Look Standard or Truncated Rule of Reason... 11-49 —
   E. Key Agency Antitrust Guidelines Relevant to Pharmaceutical Entities ................................................. 11-52 —
       1. The Antitrust Guidelines for the Licensing of Intellectual Property ........................................ 11-52 —
       2. The Statements of Antitrust Enforcement Policy in Health Care Guidelines ................................. 11-56 —
       3. The Horizontal Merger Guidelines and the Commentary on the Horizontal Merger Guidelines ................................. 11-57 —
<table>
<thead>
<tr>
<th>Section</th>
<th>Main Volume</th>
<th>Supplement</th>
</tr>
</thead>
<tbody>
<tr>
<td>4. The Guidelines for Collaborations by Competitors..........................</td>
<td>11-59</td>
<td>—</td>
</tr>
<tr>
<td>5. Other Significant Pronouncements..................................................</td>
<td>11-60</td>
<td>—</td>
</tr>
<tr>
<td>a. FTC Study: Generic Drug Entry Prior to Patent Litigation..................</td>
<td>11-60</td>
<td>—</td>
</tr>
<tr>
<td>b. FTC Study: Enforcement Perspectives on the Noerr-Pennington Doctrine...</td>
<td>11-61</td>
<td>—</td>
</tr>
<tr>
<td>F. Key Antitrust Defenses...............................................................</td>
<td>11-63</td>
<td>11-3</td>
</tr>
<tr>
<td>1. The Noerr-Pennington Doctrine...................................................</td>
<td>11-66</td>
<td>11-3</td>
</tr>
<tr>
<td>2. Patent Law......................................................................................</td>
<td>11-68</td>
<td>—</td>
</tr>
<tr>
<td>3. Antitrust Injury and Standing.....................................................</td>
<td>11-72</td>
<td>—</td>
</tr>
<tr>
<td>4. Class Action Certification...........................................................</td>
<td>11-78</td>
<td>—</td>
</tr>
<tr>
<td>G. Accountable Care Organizations....................................................</td>
<td>11-85</td>
<td>—</td>
</tr>
<tr>
<td>A. Constitutional Protection of Intellectual Property Rights.................</td>
<td>11-90</td>
<td>—</td>
</tr>
<tr>
<td>B. Statutory Protection for Patents ................................................</td>
<td>11-90</td>
<td>—</td>
</tr>
<tr>
<td>1. Patentability Standards...................................................................</td>
<td>11-90</td>
<td>—</td>
</tr>
<tr>
<td>2. Doctrine of Equivalents....................................................................</td>
<td>11-93</td>
<td>—</td>
</tr>
<tr>
<td>3. Types of Patents.............................................................................</td>
<td>11-94</td>
<td>—</td>
</tr>
<tr>
<td>4. Presumption of Validity.....................................................................</td>
<td>11-95</td>
<td>—</td>
</tr>
<tr>
<td>2. Late-Filed (Submarine) Patents.....................................................</td>
<td>11-97</td>
<td>—</td>
</tr>
<tr>
<td>3. Refusals to License.........................................................................</td>
<td>11-98</td>
<td>—</td>
</tr>
<tr>
<td>4. Patent Trolls..................................................................................</td>
<td>11-100</td>
<td>—</td>
</tr>
<tr>
<td>D. Patent Infringement Actions..........................................................</td>
<td>11-100</td>
<td>11-5</td>
</tr>
<tr>
<td>1. Sham Patent Infringement Litigation.............................................</td>
<td>11-105</td>
<td>—</td>
</tr>
<tr>
<td>2. Walker Process Counterclaims......................................................</td>
<td>11-110</td>
<td>—</td>
</tr>
<tr>
<td>3. Inequitable Conduct.........................................................................</td>
<td>11-111</td>
<td>—</td>
</tr>
<tr>
<td>5. Standing to Sue .............................................................................</td>
<td>11-118</td>
<td>—</td>
</tr>
<tr>
<td>7. Divided Infringement and Patented Precision Medicine [New Topic].....</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>IV. The Hatch-Waxman Act....................................................................</td>
<td>11-118</td>
<td>—</td>
</tr>
<tr>
<td>A. Background: Roche v. Bolar and Rejection of the “Experimental Use” Exception</td>
<td>11-119</td>
<td>—</td>
</tr>
<tr>
<td>B. Amendments to the New Drug Provisions of FD&amp;C Act Section 505(b)(1)</td>
<td>11-120</td>
<td>—</td>
</tr>
<tr>
<td>C. Duties of Manufacturers Submitting NDAs to the FDA.........................</td>
<td>11-121</td>
<td>—</td>
</tr>
<tr>
<td>D. The Orange Book (Approved Drug Products With Therapeutic Equivalence Evaluations)</td>
<td>11-122</td>
<td>—</td>
</tr>
<tr>
<td>E. Hatch-Waxman Act Mechanics...........................................................</td>
<td>11-123</td>
<td>—</td>
</tr>
<tr>
<td>1. The ANDA Process...........................................................................</td>
<td>11-124</td>
<td>—</td>
</tr>
</tbody>
</table>
b. Generic Manufacturer Must File One of Four Certifications About the Patent ................................11-125 —

2. Paragraph IV Certifications and Procedures................................. 11-126 —
  a. The 180-Day Exclusivity Period for the First Generic Applicant to Make a Paragraph IV Certification.............................................................. 11-126 —

3. The 30-Month Stay Protection ................................................. 11-128 —

4. Presumption of Validity .......................................................... 11-129 —

F. Provisions Extending Exclusivity Periods for Drug Manufacturers......................................................................................... 11-130 —
  1. New Chemical Entity Exclusivity ................................ 11-130 —
  2. Pediatric Exclusivity ..................................................... 11-131 —
  3. Orphan Drugs................................................................ 11-132 —

V. Schemes to Delay Marketing of Generics........................................ 11-133 —
  A. The Antitrust-Patent Paradox ............................................. 11-133 —
    1. Patents and Settlements Favored .................................. 11-133 —
    2. Market Divisions Disfavored ........................................ 11-134 —
    3. Application of Traditional Antitrust Standards Problematic ................................................................... 11-134 —
  B. Fraudulent Listing of Patents in the Orange Book............. 11-136 —
  C. Listing Late or Multiple (Add-On) Patents Before Drug Patents Expire......................................................... 11-138 —
  D. Authorized Generics .......................................................... 11-138 —
  E. Emerging Gaming Strategies ............................................. 11-141 —
  F. ANDA Applicant Gaming.................................................. 11-147 —
  G. Agency and Congressional Responses to Hatch-Waxman Act Problems ................................................................. 11-147 —
    1. Changes to the Hatch-Waxman Act Procedures Made by the MMA........................................................ 11-147 —
  H. Lanham Act Violations....................................................... 11-150 —

VI. Conclusion................................................................................. 11-157 —

Chapter 12. Securities Law Issues and Disclosure Considerations for Life Sciences Companies .................. 12-1 —

I. Introduction ............................................................................... 12-1 12-1

A. General Rule: No Affirmative Disclosure Duties .............. 12-5 —

B. Exceptions .......................................................................... 12-7 —

C. Common Disclosure Issues Facing Life Sciences Companies in Dealing with the FDA ................................. 12-8 12-4

1. Predictions of Drug Approvals, Denials, and Financial Estimates ........................................................................ 12-9 12-4

2. Disclosure of Clinical Tests and Results ....................... 12-12 —

3. Disclosures of Inspection and Enforcement Events .... 12-15 —

II. Overview of the Key Federal Statutes ...................................... 12-18 12-6

A. The Securities Act of 1933.................................................. 12-19 —

### Detailed Table of Contents

<table>
<thead>
<tr>
<th>Main Volume</th>
<th>Supplement</th>
</tr>
</thead>
<tbody>
<tr>
<td>III. Reporting Obligations of Publicly Traded Companies</td>
<td>12-25 12-7</td>
</tr>
<tr>
<td>A. Materiality and the Probability-Magnitude Test</td>
<td>12-25 12-7</td>
</tr>
<tr>
<td>1. Judicial Standard</td>
<td>12-25 —</td>
</tr>
<tr>
<td>2. Quantitative Standards</td>
<td>12-29 —</td>
</tr>
<tr>
<td>3. Qualitative Standards</td>
<td>12-30 —</td>
</tr>
<tr>
<td>4. Optimistic Statements Versus Specific Predictions</td>
<td>12-30 12-7</td>
</tr>
<tr>
<td>a. Soft Information and Puffery</td>
<td>12-31 —</td>
</tr>
<tr>
<td>b. The “Bespeaks Caution” Doctrine</td>
<td>12-33 —</td>
</tr>
<tr>
<td>c. Statutory Safe Harbors: Forward-Looking Statements</td>
<td>12-36 12-7</td>
</tr>
<tr>
<td>5. Third-Party Statements and the Entanglement Doctrine</td>
<td>12-42 —</td>
</tr>
<tr>
<td>B. Agency Pronouncements about Materiality</td>
<td>12-45 —</td>
</tr>
<tr>
<td>1. SEC Staff Accounting Bulletin No. 99—Materiality</td>
<td>12-45 —</td>
</tr>
<tr>
<td>2. SEC Staff Accounting Bulletin No. 100—Restructuring and Impairment Charges</td>
<td>12-46 —</td>
</tr>
<tr>
<td>3. SEC Staff Accounting Bulletin No. 101—Revenue Recognition</td>
<td>12-47 —</td>
</tr>
<tr>
<td>4. SEC Rules</td>
<td>12-49 —</td>
</tr>
<tr>
<td>a. Rule 405—Promulgated Under the Securities Act</td>
<td>12-49 —</td>
</tr>
<tr>
<td>b. Rule 408—Promulgated Under the Securities Act</td>
<td>12-49 —</td>
</tr>
<tr>
<td>c. Rules 12b-20 and 14a-9—Promulgated Under the Exchange Act</td>
<td>12-50 —</td>
</tr>
<tr>
<td>d. Rules 175 and 3b-6—Promulgated Under the Exchange Act</td>
<td>12-50 —</td>
</tr>
<tr>
<td>C. SEC-Mandated Periodic Disclosure of Specified Information</td>
<td>12-51 —</td>
</tr>
<tr>
<td>1. Regulation S-K</td>
<td>12-52 —</td>
</tr>
<tr>
<td>a. Item 10b</td>
<td>12-53 —</td>
</tr>
<tr>
<td>b. Item 103</td>
<td>12-53 —</td>
</tr>
<tr>
<td>c. Item 303</td>
<td>12-54 —</td>
</tr>
<tr>
<td>d. Item 401(f)</td>
<td>12-56 —</td>
</tr>
<tr>
<td>e. Item 404(a) and Self-Dealing</td>
<td>12-56 —</td>
</tr>
<tr>
<td>f. Item 503(c)</td>
<td>12-56 —</td>
</tr>
<tr>
<td>2. Regulation S-X</td>
<td>12-58 —</td>
</tr>
<tr>
<td>a. Article 3</td>
<td>12-58 —</td>
</tr>
<tr>
<td>b. Article 10</td>
<td>12-58 —</td>
</tr>
<tr>
<td>3. Periodic Forms</td>
<td>12-59 —</td>
</tr>
<tr>
<td>a. Form 8-K</td>
<td>12-59 —</td>
</tr>
<tr>
<td>b. Form 10-Q</td>
<td>12-60 —</td>
</tr>
<tr>
<td>c. Form 10-K</td>
<td>12-60 —</td>
</tr>
<tr>
<td>4. Regulation FD</td>
<td>12-61 —</td>
</tr>
<tr>
<td>D. How to Make Disclosures</td>
<td>12-62 —</td>
</tr>
<tr>
<td>1. Duty to Update</td>
<td>12-64 —</td>
</tr>
<tr>
<td>2. Duty to Correct</td>
<td>12-65 —</td>
</tr>
<tr>
<td>IV. Securities Fraud and Anti-Manipulation Rules</td>
<td>12-65 12-8</td>
</tr>
<tr>
<td>A. Manipulative Conduct</td>
<td>12-66 —</td>
</tr>
<tr>
<td>B. Key Provisions</td>
<td>12-68 —</td>
</tr>
<tr>
<td>1. Exchange Act Section 9</td>
<td>12-68 —</td>
</tr>
<tr>
<td>2. Exchange Act Section 10(b)</td>
<td>12-68 —</td>
</tr>
<tr>
<td>3. Exchange Act Section 14(e)</td>
<td>12-69 —</td>
</tr>
</tbody>
</table>
4. Securities Act Section 11 .............................................. 12-70 —
5. Securities Act Section 12(a)(2) ..................................... 12-71 —
6. Securities Act Section 17(a)(2) ..................................... 12-71 —
C. Scienter .............................................................................. 12-72 —
D. The Fraud-on-the-Market Theory and the Fraud-Created-
the-Market Theory ............................................................. 12-77 —
E. Primary and Secondary Liability Issues ....................... 12-81 —
1. Central Bank ................................................................. 12-82 —
2. Control Person Liability ............................................... 12-83 —
3. SEC v. Zandford and Primary Liability Under Sections
   10(a) and (c).................................................................. 12-87 —
V. Defenses to Securities Fraud Cases................................. 12-89 —
A. Truth on the Market ........................................................... 12-89 —
B. Lack of Materiality ............................................................ 12-90 —
C. Failure to Establish Essential Elements ....................... 12-91 —
VI. Insider Trading ................................................................. 12-100 —
A. Statutory Insiders: Section 16 and the Prohibition
   Against Short Swing Trading ............................................ 12-101 —
B. The Disclose-or-Abstain Rule ............................................ 12-103 —
C. Duty to Disclose Material Facts ..................................... 12-103 —
   1. Insider Trading of Company Securities Based on
      Material Nonpublic Information................................. 12-104 —
   2. When Applicable Statute or Regulation Mandates
      Disclosure .................................................................... 12-105 —
   3. When Prior Statement of Material Fact Becomes
      False or Misleading in Light of Undisclosed
      Information ................................................................... 12-105 —
D. The Classical Theory of Insider Trading Liability ............. 12-105 —
E. The Misappropriation Theory of Insider Trading
   Liability ............................................................................. 12-106 —
F. Differences Between the Use and Mere Possession
   of Nonpublic Information.............................................. 12-107 —
   1. The Knowing Possession Standard............................. 12-107 —
   2. The Use Test ................................................................. 12-108 —
G. SEC Rule 10b5–1 and the Affirmative Defense for
   Written Preexisting Stock Trading Plans ....................... 12-108 —
VII. Private Suits and the Private Securities Litigation Reform
    Act of 1995 ........................................................................ 12-109 —
    A. Class Actions................................................................. 12-114 —
VIII. SEC Enforcement ........................................................... 12-120 —
    A. Administrative Proceedings ............................................ 12-123 —
    B. Three-Tier Monetary Penalties ..................................... 12-126 —
    C. Agency Civil Remedies ................................................ 12-126 —
    D. Dodd-Frank Act Provisions ......................................... 12-126 —
       1. Whistleblower Provisions ....................................... 12-126 —
       2. Aiding and Abetting Liability Authorized ............... 12-129 —
       3. Extraterritorial Reach (Limited Repeal of Morrison) ... 12-130 —
IX. Criminal Violations .......................................................... 12-130 —
    A. Securities Fraud Based on Rule 10b-5 Violations .......... 12-133 —
    B. Insider Trading ............................................................ 12-133 —
    C. Foreign Corrupt Practices Act ...................................... 12-135 —
Chapter 13. The Regulation of Biologics

I. Introduction
II. Regulatory Approach
III. Regulatory Authority and Organizations
   A. Sources of Regulatory Authority
   B. Responsible Regulatory Organizations
   C. Biologics License
IV. Types of Biologics and Associated Regulatory Approaches
   A. Human Cells, Tissues, and Cellular and Tissue-Based Products
      1. Regulatory Approach
      2. 21 C.F.R. §1271 Subpart B: Procedures for Registration and Listing
      3. 21 C.F.R. §1271 Subpart C: Donor Eligibility
      4. 21 C.F.R. §1271 Subpart D: Current Good Tissue Practice
      5. 21 C.F.R. §1271 Subpart E: Additional Requirements for Establishments Described in Section 1271.10
      6. 21 C.F.R. §1271 Subpart F: Inspection and Enforcement of Establishments Described in Section 1271.10
      7. Compliance
      8. Uniform Anatomical Gift Act
      9. Human Embryonic Stem Cell Funding
   B. Blood and Blood Components
      1. U.S. Blood System
      2. Authority; Blood Establishment Registration and Blood Product Listing
      3. Blood Safety Measures
         a. Donor Suitability Standards
         b. Deferred Donor List
         c. Testing
         d. Quarantine
         e. Oversight
      4. Current Good Manufacturing Processes for Blood and Blood Products
      5. Blood and Blood Products as Drugs and Devices
      7. Managing Blood Supply Risks [Substitute Text]
      8. Compliance
   C. General Requirements for Biologic Products; Vaccines, Viruses, and Spores
      1. Regulatory Approach
         a. Personnel and Facilities
         b. Personnel Working With Pathogenic Viruses and Spore-Forming Organisms
         c. Live Vaccine Personnel and Facilities
         d. Animals Used in Vaccine Manufacturing
2. Records ................................................................. 13-29 —
3. Samples .................................................................... 13-29 —
4. Reporting .................................................................. 13-30 —
5. Additional Regulations Regarding Vaccines ............. 13-30 —
   a. National Childhood Vaccine Injury Act ................. 13-30 —
   b. Vaccine Adverse Event Reporting System ............ 13-30 —
   c. National Vaccine Injury Compensation System .... 13-31 —
   d. National Vaccine Program ................................. 13-31 —
   e. Regulatory Review of Pre-July 1, 1972, Bacterial
      Vaccines and Toxoids ...................................... 13-32 —
D. Drugs ....................................................................... 13-32 —
E. Gene Therapy and Cellular Therapy .......................... 13-33 —
F. Human Organs for Transplantation ......................... 13-34 —
   1. Health Resources and Services Administration and
      the National Organ Transplant Act ................. 13-34 —
   2. Human Organs and Blood Vessels for Transplant ... 13-35 —
   3. Bone Marrow and Cord Blood Donation and
      Transplantation Program ............................... 13-35 —
G. Xenotransplantation .................................................. 13-35 —
H. Combination Products .............................................. 13-37 —
   1. Office of Combination Products and Method of
      Assignment ................................................... 13-37 —
   2. Assignment Criteria .......................................... 13-37 —
V. Biological Products Regulated as Devices .................... 13-38 —
VI. Regulatory Approval Path for Generic Biologics
    [Amended Topic] [Substitute Text] ............................ 13-39 13-8
VII. Intellectual Property Regulations of Biologics in the
     United States and Abroad ...................................... 13-40 13-13

Chapter 14. Pharmaceutical Compounding—Understanding the
Blurred Line Between Manufacturing and
Traditional Pharmacy Practice ..................................... 14-1 14-1

I. Introduction .................................................................. 14-2 14-3
II. Manufacturing Versus Compounding Under Federal Law ... 14-5 14-3
   A. Manufacturing ................................................. 14-5 14-3
   B. Compounding ................................................... 14-6 14-4
III. The Drug Quality and Security Act ............................... 14-7 14-4
      1. Draft Guidance: Insanitary Conditions at Compounding
      2. Draft Guidance: Repackaging of Certain Human
         Drug Products by Pharmacies and Outsourcing
      3. Draft Guidance: Mixing, Diluting, or Repackaging
         Biological Products Outside the Scope of an Approved
   B. Traditional Compounders Under Section 503A
      [Renumbered Topic] ............................................. 14-8 14-6
      1. Final Guidance: Pharmacy Compounding of
         Human Drug Products Under Section 503A ......... 14-9 —
<table>
<thead>
<tr>
<th>Main Volume</th>
<th>Supplement</th>
</tr>
</thead>
<tbody>
<tr>
<td>14-10</td>
<td>—</td>
</tr>
<tr>
<td>14-10</td>
<td>—</td>
</tr>
<tr>
<td>14-11</td>
<td>—</td>
</tr>
<tr>
<td>14-12</td>
<td>—</td>
</tr>
<tr>
<td>—</td>
<td>14-6</td>
</tr>
<tr>
<td>—</td>
<td>14-7</td>
</tr>
<tr>
<td>—</td>
<td>14-8</td>
</tr>
<tr>
<td>—</td>
<td>14-10</td>
</tr>
<tr>
<td>14-10</td>
<td>—</td>
</tr>
<tr>
<td>14-12</td>
<td>14-11</td>
</tr>
<tr>
<td>14-14</td>
<td>—</td>
</tr>
<tr>
<td>14-15</td>
<td>—</td>
</tr>
<tr>
<td>14-15</td>
<td>—</td>
</tr>
<tr>
<td>14-16</td>
<td>—</td>
</tr>
<tr>
<td>—</td>
<td>14-12</td>
</tr>
<tr>
<td>—</td>
<td>14-13</td>
</tr>
<tr>
<td>—</td>
<td>14-14</td>
</tr>
<tr>
<td>—</td>
<td>14-15</td>
</tr>
<tr>
<td>—</td>
<td>14-16</td>
</tr>
<tr>
<td>14-17</td>
<td>14-16</td>
</tr>
<tr>
<td>14-18</td>
<td>14-17</td>
</tr>
</tbody>
</table>
Chapter 15. Regulation of Dietary Supplements

I. Introduction ................................................................. 15-2
II. Legislative History ....................................................... 15-2
   A. Congressional Intent .................................................. 15-2
   B. Early Efforts ............................................................... 15-3
   C. Judicial Intervention ................................................... 15-4
III. Understanding DSHEA Requirements .................................. 15-5
   A. Definitions ................................................................. 15-5
   B. Judicial Interpretations ............................................... 15-6
IV. Safety Standards and Burden of Proof ............................... 15-7
   A. Supplement Safety Standards ....................................... 15-7
   B. Burden of Proof.......................................................... 15-7
   C. Ephedrine Alkaloids Safety ......................................... 15-8
   D. EDS Cases .................................................................. 15-9
V. Labeling Requirements Under DSHEA ................................. 15-11
   A. Prior Labeling Requirements ....................................... 15-11
   B. Labeling Requirements Under DSHEA ......................... 15-12
   C. Emerging Health Claims ............................................. 15-14
   D. Labeling Exceptions Under DSHEA .............................. 15-15
VI. Dietary Supplement Labeling ............................................. 15-15
   A. Misbranding of Supplements ...................................... 15-15
   B. Ingredient Labeling.................................................... 15-16
VII. New Dietary Ingredients .................................................. 15-17
VIII. Adverse Event Reporting ............................................... 15-17
IX. Good Manufacturing Processes ........................................ 15-18
X. Enforcement of DSHEA .................................................. 15-19
   A. FDA Role ................................................................. 15-19
   B. Federal Trade Commission .......................................... 15-21
Detailed Table of Contents

Main
Volume
Supple-
ment

C. Office of Dietary Supplements ........................................... 15-22 —
D. Commission on Dietary Supplement Labels .......................... 15-23 —
XI. Criticisms of DSHEA .................................................. 15-23 —
   A. Lack of Regulatory Oversight ........................................ 15-23 —
   B. Lack of Statutory Clarity ............................................. 15-24 —
XII. Conclusions [Substitute Text] ........................................... 15-25 15-10

Chapter 16. Ethics in Research ............................................ 16-1 16-1
   I. Introduction ....................................................................... 16-1 —
   II. Underlying Ethical Principles and Their Reflection in Law .... 16-2 16-1
      A. Autonomy and Informed Consent .................................. 16-2 16-1
      B. Respect for Privacy .................................................... 16-5 —
      C. Beneficence (Doing Good) and Nonmaleficence
         (Preventing or Mitigating Harm) ............................... 16-7 —
      D. Fidelity and Integrity ............................................... 16-8 16-3
   III. Conclusion ..................................................................... 16-9 —

Chapter 17. Medical Devices ............................................. 17-1 17-1
   I. Introduction ....................................................................... 17-2 —
   II. FDA Role in Regulating Medical Devices ......................... 17-2 17-3
      A. CDRH Structure ......................................................... 17-3 —
      B. What Is a Medical Device? ......................................... 17-3 —
      C. Bringing a Device to Market ....................................... 17-4 17-3
         1. Step 1: Risk Classification ...................................... 17-4 17-3
            a. Device Regulations, Classifications, and
               Product Codes .................................................. 17-4 —
            b. Intended Use and Indications for Use .................. 17-4 17-3
               i. Intended Use [Substitute Text] ....................... 17-6 17-3
               ii. Indications for Use [Substitute Text] .......... 17-6 17-3
               iii. Intended Use Versus Indications for Use ...... 17-6 —
            c. Risk Categorization [Substitute Text] .......... 17-6 17-3
               i. Class I .................................................. 17-7 —
               ii. Class II ................................................... 17-7 —
               iii. Class III .................................................. 17-7 —
            d. Controls .......................................................... 17-7 —
               i. General Controls ......................................... 17-8 —
               ii. Special Controls ......................................... 17-8 —
         2. Step 2: Premarket Submission ..................................... 17-8 —
            a. PMA .......................................................... 17-8 —
            b. 510(k) ......................................................... 17-8 —
               i. Least Burdensome Principle .......................... 17-9 —
               ii. Predicate Devices ....................................... 17-9 —
               iii. Reference Devices ...................................... 17-9 —
               iv. Substantial Equivalence ............................. 17-9 —
               v. Non-Substantial Equivalence ...................... 17-9 —
            c. De Novo Process ............................................. 17-12 —
         3. Step 3: Premarket Packet ........................................... 17-14 —
            a. Traditional 510k Application ............................ 17-14 —
Chapter 18.  A Comprehensive Overview of Pharmaceuticals
Reimbursement [New Chapter]................................. — 18-1

I. Introduction .............................................................. — 18-3

II. Primary Players in the Pharmaceutical Industry ............. — 18-4
A. Manufacturers .......................................................... — 18-4
B. Wholesale Distributors ............................................. — 18-4
C. Third-Party Payors .................................................... — 18-5
D. Pharmacy Benefits Managers and Payors .................... — 18-5
E. Group Purchasing Organizations ................................. — 18-6
F. Pharmacies ............................................................... — 18-6

III. Pricing Pharmaceuticals ............................................. — 18-7
A. Pricing Strategies ..................................................... — 18-7
1. Rare Diseases ......................................................... — 18-7
2. “Breakthrough” Niche Markets: Harvoni ..................... — 18-8
3. Generics Competition ............................................... — 18-10
4. Branded Generics .................................................... — 18-10
5. Over-the-Counter Drugs .......................................... — 18-11
B. Abusive Pricing Practices ........................................... — 18-12
### Detailed Table of Contents

<table>
<thead>
<tr>
<th>Main Volume</th>
<th>Supplement</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

1. Abusing the Orphan Drug Act: Marathon Pharmaceuticals ............................................................ — 18-12
3. Predatory Pricing: Valeant and Turing Pharmaceuticals ............................................................ — 18-14

C. Government Efforts to Fight Abusive Pricing ............ — 18-15
   1. President .......................................................................  — 18-16
   2. Congress .......................................................................  — 18-16
   3. States ............................................................................. — 18-18
   4. Federal Agencies ........................................................... — 18-20
   5. Private Payors ............................................................... — 18-20

IV. Reimbursement ........................................ — 18-21
   A. An Introduction to Pharmaceuticals Reimbursement ...... — 18-21
      1. How Consumers Obtain Coverage and Insurers Obtain Payment for Drugs ................................ — 18-21
      2. Reimbursement to Providers ....................................... — 18-23
   B. Who Determines Reimbursement ...................................... — 18-24
      1. Government Payors .................................................... — 18-24
         a. Medicare ............................................................... — 18-24
            i. Medicare Part D: The Medicare Prescription Drug Benefit ...................................................... — 18-25
            ii. Price Reform for Part B Outpatient Drugs Under the MMA ................................................ — 18-25
         b. Medicaid ............................................................... — 18-27
            i. Federally Mandated State Program Organizational Requirements ........................................ — 18-27
            iii. State Supplemental Drug Rebate Agreements .............................................................. — 18-29
            iv. State Pharmaceutical Assistance Programs ............................................................. — 18-29
         c. TriCare ................................................................. — 18-29
         d. Private Payors ......................................................... — 18-30
   C. How Are Pharmaceuticals Reimbursed? ............................ — 18-30
      1. Bundling ................................................................. — 18-30
      2. Outpatient Prospective Payment System Payment Status Indicators ................................—— — 18-32
      3. ICD-10 Codes ............................................................ — 18-32
      4. HCPCS and CPT Codes ................................................ — 18-33
      5. National and Local Coverage Decisions ........................... — 18-34
         a. National Coverage Decisions ................................... — 18-34
         b. Local Coverage Decisions ....................................... — 18-35
         c. Other NCD and LCD Coverage Determinants ........ — 18-37
         d. Appealing National and Local Coverage Decisions ................................................ — 18-37
   V. Costing Pharmaceuticals ........................................................... — 18-39
      A. Federal Upper Limits ......................................................... — 18-39
      B. Maximum Allowable Cost ................................................ — 18-40
      C. National Average Drug Acquisition Cost ................................ — 18-40
      D. The Average Sales Price System ........................................ — 18-41
      E. Competitive Acquisition Program ........................................ — 18-43
F. Average Wholesale Price ................................................... — 18-43

VI. Getting Pharmaceuticals Onto a Formulary.............................. — 18-44
   A. An Introduction to Health Economics ............................... — 18-44
      1. Quality-Adjusted Life Years ......................................... — 18-44
      2. Deductibles ................................................................... — 18-45
      3. Prior Authorizations...................................................... — 18-45

VII. Special Reimbursement Situations ............................................. — 18-45
   A. Clinical Trials ..................................................................... — 18-46
   B. Diabetic Supplies ............................................................... — 18-47
   C. End-of-Life Medications.................................................... — 18-47

VIII. Fraud and Abuse .................................................................. — 18-48
   A. Laws ................................................................................... — 18-48
   B. Current Enforcement .......................................................... — 18-51
   C. Updates .............................................................................. — 18-53
   D. Joint FDA/CMS Pilot......................................................... — 18-53

IX. FDA Policy on Drug Importation and Modern Tensions .......... — 18-54
   A. General Prohibition on Reimportation: The Prescription
      Drug Marketing Act of 1987 ............................................. — 18-55
   B. Exceptions to the PDMA ................................................... — 18-55
      1. Imports of Pharmaceuticals and Medical Devices by
         Original Manufacturers................................................ — 18-55
      2. Reimportation for Emergency Use ................................ — 18-56
   C. Modern Tensions in Drug Importation ............................... — 18-56
      1. Ineffective Commercial Importation Authorization...... — 18-56
      2. Importation for Personal Use......................................... — 18-60

X. Conclusion ................................................................................. — 18-62

Appendix Table of Contents .............................................................. App-1 —

Appendix A: Clinical Research ......................................................... A-1 —

A-1 Sample Informed Consent and Authorization Form for
Clinical Research.............................................................................. A-3 —

Appendix B: Enforcement Actions ................................................... B-1 —

B-1 Horizontal Merger Guidelines (August 19, 2010)..................... B-3 —

Table of Cases ................................................................................. TC-1 TC-1

Index .................................................................................................... IN-1 —